Fda grants orphan drug designation for can-3110 for the treatment of recurrent high-grade glioma

Needham, mass., may 30, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation to can-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma (rhgg). glioblastoma (gbm) is the most common and aggressive form of high-grade glioma.
CADL Ratings Summary
CADL Quant Ranking